DOI QR코드

DOI QR Code

Steroid Receptor Coactivator-3 Promotes Bladder Cancer Through Upregulation of CXCR4

  • Zhang, Yu (Department of Urology, Shanghai Changning Center Hospital) ;
  • Wang, Ji-Hong (Department of Urology, Shanghai Jiao Tong University Affiliated 6th People's Hospital) ;
  • Liu, Bin (Shanghai Institute of Materia Medica Chinese Academy of Sciences) ;
  • Qu, Ping-Bao (Department of Urology, Shanghai Changning Center Hospital)
  • Published : 2013.06.30

Abstract

The three homologous members of the p160 SRC family (SRC-1, SRC-2 and SRC-3) mediate the transcriptional functions of nuclear receptors and other transcription factors, and are the most studied of all the transcriptional co-activators. Recent work has indicated that the SRC-3 gene is subject to amplification and overexpression in various human cancers. Some of the molecular mechanisms responsible for SRC overexpression, along with the mechanisms by which SRC-3 promotes breast and prostate cancer cell proliferation and survival, have been identified. However, the function of SRC-3 in bladder cancer remains poorly understood. In the present study, our results indicate that overexpression of SRC-3 promotes bladder cancer cell proliferation whereas knockdown of SRC-3 results in inhibition. At the molecular level, we further established that CXCR4 is a transcriptional target of SRC-3. Therefore, our study first identified that SRC-3 plays a critical role in the bladder cancer, which may be a target beneficial for its prevention and treatment.

Keywords

SRC-3;bladder cancer;CXCR4

References

  1. Cai D, Shames DS, Raso MG, et al (2010). Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res, 70, 6477-85. https://doi.org/10.1158/0008-5472.CAN-10-0005
  2. Coste A, Louet JF, Lagouge M, et al (2008). The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}. Proc Natl Acad Sci U S A, 105, 17187-92. https://doi.org/10.1073/pnas.0808207105
  3. Eisenhardt A, Frey U, Tack M, et al (2005). Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol, 47, 111-7. https://doi.org/10.1016/j.eururo.2004.10.001
  4. Geng C, He B, Xu L, et al (2013). Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A, 110, 6997-7002. https://doi.org/10.1073/pnas.1304502110
  5. Gojis O, Rudraraju B, Gudi M, et al (2010). The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol, 7, 83-9. https://doi.org/10.1038/nrclinonc.2009.219
  6. Kuang SQ, Liao L, Zhang H, et al (2004). AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res, 64, 1875-85. https://doi.org/10.1158/0008-5472.CAN-03-3745
  7. Kucukgergin C, Isman FK, Dasdemir S, et al (2012). The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene, 511, 7-11. https://doi.org/10.1016/j.gene.2012.09.011
  8. Lanz RB, Bulynko Y, Malovannaya A, et al (2010). Global characterization of transcriptional impact of the SRC-3 coregulator. Mol Endocrinol, 24, 859-72. https://doi.org/10.1210/me.2009-0499
  9. Lonard DM, O'Malley BW (2012). Nuclear receptor coregulators: modulators of pathology and therapeutic targets. Nat Rev Endocrinol, 8, 598-604. https://doi.org/10.1038/nrendo.2012.100
  10. Long W, Foulds CE, Qin J, et al (2012).ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest, 122, 1869-80. https://doi.org/10.1172/JCI61492
  11. Lydon JP, O'Malley BW (2011). Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis. Endocrinology, 152, 19-25. https://doi.org/10.1210/en.2010-1012
  12. Ma G, Ren Y, Wang K, He J (2011). SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int J Biol Sci, 7, 664-72.
  13. McBryan J, Theissen SM, Byrne C, et al (2012). Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res, 72, 548-59. https://doi.org/10.1158/0008-5472.CAN-11-2073
  14. Moi LL, Flågeng MH, Gjerde J, et al (2012). Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer, 15, 12:247.
  15. Mussi P, Yu C, O'Malley BW, Xu J (2006). Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol, 20, 3105-19. https://doi.org/10.1210/me.2005-0522
  16. Nishizawa K, Nishiyama H, Oishi S, et al (2010). Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4. Int J Cancer, 127, 1180-7.
  17. Palmieri C, Gojis O, Rudraraju B, et al (2013). Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br J Cancer, 108, 2039-44. https://doi.org/10.1038/bjc.2013.199
  18. Parkin DM, Pisani P, Ferlay J (2008). Global cancer statistics. CA Cancer J Clin, 49, 33-64.
  19. Qin L, Liu Z, Chen H, Xu J (2009). The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res, 69, 3819-27. https://doi.org/10.1158/0008-5472.CAN-08-4389
  20. Retz MM, Sidhu SS, Blaveri E, et al (2005). CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer, 114, 182-9. https://doi.org/10.1002/ijc.20729
  21. Shen HB, Gu ZQ, Jian K, Qi J (2013). CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer. Tumour Biol, 34, 1839-45. https://doi.org/10.1007/s13277-013-0725-z
  22. Walsh CA, Qin L, Tien JC, Young LS, Xu J (2012). The function of steroid receptor coactivator-1 in normal tissues and cancer. Int J Biol Sci, 8, 470-85. https://doi.org/10.7150/ijbs.4125
  23. Wang H, Yang D, Wang K, Wang J (2011). Expression and potential role of chemokine receptor CXCR4 in human bladder carcinoma cell lines with different metastatic ability. Mol Med Rep, 4, 525-8.
  24. Wu RC, Feng Q, Lonard DM, O'Malley BW (2007). SRC-3 coactivator functional lifetime is regulated by a phosphodependent ubiquitin time clock. Cell, 129,1125-40. https://doi.org/10.1016/j.cell.2007.04.039
  25. Xu J, Wu RC, O'Malley BW (2009). Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer, 9, 615-30. https://doi.org/10.1038/nrc2695
  26. Yates TJ, Knapp J, Gosalbez M, et al (2013). C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer, 119, 61-71. https://doi.org/10.1002/cncr.27661
  27. Yi P, Feng Q, Amazit L, et al (2008). Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol Cell, 29, 465-76. https://doi.org/10.1016/j.molcel.2007.12.030
  28. Yi P, Xia W, Wu RC, Lonard DM, Hung MC, et al (2013). SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes Dev, 27, 274-87. https://doi.org/10.1101/gad.203760.112
  29. York B, O'Malley BW (2010). Steroid receptor coactivator (SRC) family: masters of systems biology. J Biol Chem, 285, 38743-50. https://doi.org/10.1074/jbc.R110.193367

Cited by

  1. Steroid Hormone Receptor Coregulators in Endocrine Cancers vol.68, pp.7, 2016, https://doi.org/10.1002/iub.1517